440 related articles for article (PubMed ID: 25452729)
21. Crosstalk Between Kappa Opioid and Dopamine Systems in Compulsive Behaviors.
Escobar ADP; Casanova JP; Andrés ME; Fuentealba JA
Front Pharmacol; 2020; 11():57. PubMed ID: 32132923
[TBL] [Abstract][Full Text] [Related]
22. The kappa opioid receptor is associated with the perception of visceral pain.
Black D; Trevethick M
Gut; 1998 Sep; 43(3):312-3. PubMed ID: 9863470
[TBL] [Abstract][Full Text] [Related]
23. Role of kappa-opioid receptors in stress and anxiety-related behavior.
Van't Veer A; Carlezon WA
Psychopharmacology (Berl); 2013 Oct; 229(3):435-52. PubMed ID: 23836029
[TBL] [Abstract][Full Text] [Related]
24. κ-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition.
Abraham AD; Fontaine HM; Song AJ; Andrews MM; Baird MA; Kieffer BL; Land BB; Chavkin C
Neuropsychopharmacology; 2018 Jan; 43(2):362-372. PubMed ID: 28649993
[TBL] [Abstract][Full Text] [Related]
25. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.
Bruchas MR; Land BB; Chavkin C
Brain Res; 2010 Feb; 1314():44-55. PubMed ID: 19716811
[TBL] [Abstract][Full Text] [Related]
26. Dynorphin activation of kappa opioid receptor reduces neuronal excitability in the paraventricular nucleus of mouse thalamus.
Chen Z; Tang Y; Tao H; Li C; Zhang X; Liu Y
Neuropharmacology; 2015 Oct; 97():259-69. PubMed ID: 26056031
[TBL] [Abstract][Full Text] [Related]
27. Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening.
Spetea M; Asim MF; Noha S; Wolber G; Schmidhammer H
Curr Pharm Des; 2013; 19(42):7362-72. PubMed ID: 23448472
[TBL] [Abstract][Full Text] [Related]
28. Kappa Opioid Receptor Mediated Differential Regulation of Serotonin and Dopamine Transporters in Mood and Substance Use Disorder.
Ragu Varman D; Jayanthi LD; Ramamoorthy S
Handb Exp Pharmacol; 2022; 271():97-112. PubMed ID: 34136961
[TBL] [Abstract][Full Text] [Related]
29. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
Ko MC; Husbands SM
J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
[TBL] [Abstract][Full Text] [Related]
30. Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry.
Tejeda HA; Wang H; Flores RJ; Yarur HE
Handb Exp Pharmacol; 2022; 271():223-253. PubMed ID: 33580392
[TBL] [Abstract][Full Text] [Related]
31. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
32. Neurobiology of Opioid Addiction: Opponent Process, Hyperkatifeia, and Negative Reinforcement.
Koob GF
Biol Psychiatry; 2020 Jan; 87(1):44-53. PubMed ID: 31400808
[TBL] [Abstract][Full Text] [Related]
33. Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders.
Tejeda HA; Bonci A
Brain Res; 2019 Jun; 1713():91-101. PubMed ID: 30244022
[TBL] [Abstract][Full Text] [Related]
34. Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats.
Jolivalt CG; Jiang Y; Freshwater JD; Bartoszyk GD; Calcutt NA
Diabetologia; 2006 Nov; 49(11):2775-85. PubMed ID: 16924480
[TBL] [Abstract][Full Text] [Related]
35. Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses.
Dunn AD; Reed B; Erazo J; Ben-Ezra A; Kreek MJ
ACS Chem Neurosci; 2019 Aug; 10(8):3590-3600. PubMed ID: 31313902
[TBL] [Abstract][Full Text] [Related]
36. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder.
Browne CA; Wulf H; Lucki I
Handb Exp Pharmacol; 2022; 271():493-524. PubMed ID: 33580854
[TBL] [Abstract][Full Text] [Related]
37. Effects of combined opioids on pain and mood in mammals.
Rech RH; Mokler DJ; Briggs SL
Pain Res Treat; 2012; 2012():145965. PubMed ID: 22550575
[TBL] [Abstract][Full Text] [Related]
38. Dynorphin/kappa opioid receptor system regulation on amygdaloid circuitry: Implications for neuropsychiatric disorders.
Limoges A; Yarur HE; Tejeda HA
Front Syst Neurosci; 2022; 16():963691. PubMed ID: 36276608
[TBL] [Abstract][Full Text] [Related]
39. Opioids in chronic pain.
Przewłocki R; Przewłocka B
Eur J Pharmacol; 2001 Oct; 429(1-3):79-91. PubMed ID: 11698029
[TBL] [Abstract][Full Text] [Related]
40. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.
Tejeda HA; Chefer VI; Zapata A; Shippenberg TS
Psychopharmacology (Berl); 2010 Jun; 210(2):231-40. PubMed ID: 20232058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
